The bZIP Transactivator of Epstein-Barr Virus, BZLF1, Functionally and Physically Interacts with the p65 Subunit of NF-kB

REFERENCES

• Artandi, S., and K. Calame. 1993. Glutathione S-transferase fusion protein affinity chromatography to assess biochemical interactions between DNA-binding proteins, p. 267–279. In K. W. Adolph (ed.), Methods in molecular genetics. Academic Press, Inc., San Diego, Calif.
   Google Scholar
• Baeuerle, P. A. 1991. The inducible transcription activator NF- kappa B: regulation by distinct protein subunits. Biochim. Biophys. Acta 1072:63–80.
   PubMed Web of Science ®Google Scholar
• Baeuerle, P. A., and D. Baltimore. 1988. IκB: a specific inhibitor of the NF-κB transcription factor. Science 242:540–546.
   PubMed Web of Science ®Google Scholar
• Baeuerle, P. A., and D. Baltimore. 1989. A 65-kD subunit of active NF-kB is required for inhibition of NF-κB by IκB. Genes Dev. 3:1689–1698.
   PubMed Web of Science ®Google Scholar
• Baldwin, A. S., and P. A. Sharp. 1988. Two transcription factors, NF-κB and H2TF1, interact with a single regulatory sequence in the class I major histocompatibility complex promoter. Proc. Natl. Acad. Sci. USA 85:723–727.
   PubMedGoogle Scholar
• Beg, A. A., S. M. Ruben, R. I. Scheinman, S. Haskill, C. A. Rosen, and A. S. Baldwin. 1992. IκB interacts with the nuclear localization sequences of the subunits of NF-κB: a mechanism for cytoplasmic retention. Genes Dev. 6:1899–1913.
   PubMed Web of Science ®Google Scholar
• Bengal, E., L. Ransone, R. Scharfmann, V. J. Dwarki, S. J. Tapscott, H. Weintraub, and I. M. Verma. 1992. Functional antagonism between c-jun and MyoD proteins: a direct physical association. Cell 68:507–519.
   PubMed Web of Science ®Google Scholar
• Blanar, M. A., and W. J. Rutter. 1992. Interaction cloning: identification of a helix-loop-helix zipper protein that interacts with c-fos. Science 256:1014–1018.
   PubMedGoogle Scholar
• Buisson, M., E. Manet, M. Trescol-Biemont, H. Gruffat, B. Durand, and A. Sergeant. 1989. The Epstein-Barr virus (EBV) early protein EB2 is a posttranscriptional activator expressed under the control of EBV transcription factors EB1 and R. J. Virol. 63:5276–5284.
   PubMedGoogle Scholar
• Chang, Y. N., D. L. Dong, G. S. Hayward, and S. D. Hayward. 1990. The Epstein-Barr virus Zta transactivator: a member of the bZIP family with unique DNA-binding specificity and a dimerization domain that lacks the characteristic heptad leucine zipper motif. J. Virol. 64:3358–3369.
   PubMed Web of Science ®Google Scholar
• Chavrier, P., H. Gruffat, A. Chevallier-Greco, M. Buisson, and A. Sergeant. 1989. The Epstein-Barr virus (EBV) early promoter DR contains a czs-acting element responsive to the EBV transactivator EB1 and an enhancer with constitutive and inducible activities. J. Virol. 63:607–614.
   PubMedGoogle Scholar
• Cherrington, J. M., and E. S. Mocarski. 1989. Human cytomegalovirus ie 1 transactivates the a promoter-enhancer via an 18-base- pair repeat element. J. Virol. 63:1435–1440.
   PubMedGoogle Scholar
• Chevallier-Greco, A., H. Gruffat, E. Manet, A. Calender, and A. Sergeant. 1989. The Epstein-Barr virus (EBV) DR enhancer contains two functionally different domains: domain A is constitutive and cell specific, domain B is transactivated by the EBV early protein R. J. Virol. 63:615–623.
   PubMedGoogle Scholar
• Chevallier-Greco, A., E. Manet, P. Chavrier, C. Mosnier, J. Daillie, and A. Sergeant. 1986. Both Epstein-Barr virus (EBV)- encoded trans-acting factors, EB1 and EB2, are required to activate transcription from an EBV early promoter. EMBO J. 5:3243–3249.
   PubMed Web of Science ®Google Scholar
• Countryman, J., and G. Miller. 1985. Activation of expression of latent Epstein-Barr herpesvirus after gene transfer with a small cloned subfragment of heterogeneous viral DNA. Proc. Natl. Acad. Sci. USA 82:4085–4089.
   PubMedGoogle Scholar
• Cox, M. A., J. Leahy, and J. M. Hardwick. 1990. An enhancer within the divergent promoter of Epstein-Barr virus responds synergistically to the R and Z transactivators. J. Virol. 64:313–321.
   PubMedGoogle Scholar
• Daibata, M., R. E. Humphreys, and T. Sairenji. 1992. Phosphorylation of the Epstein-Barr virus BZLF1 immediate-early gene product ZEBRA. Virology 188:916–920.
   PubMedGoogle Scholar
• Farrell, P. J., D. T. Rowe, C. M. Rooney, and T. Kouzarides. 1989. Epstein-Barr virus BZLF1 trans-activator specifically binds to a consensus AP-1 site and is related to c-fos. EMBO J. 8:127–132.
   PubMed Web of Science ®Google Scholar
• Flemington, E., and S. H. Speck. 1990. Autoregulation of Epstein-Barr virus putative lytic switch gene BZLF1. J. Virol. 64:1227–1232.
   PubMedGoogle Scholar
• Flemington, E., and S. H. Speck. 1990. Evidence for coiled-coil dimer formation by an Epstein-Barr virus transactivator that lacks a heptad repeat of leucine residues. Proc. Natl. Acad. Sci. USA 87:9459–9463.
   PubMedGoogle Scholar
• Ghosh, S., A. M. Gifford, L. R. Riviere, P. Tempst, G. P. Nolan, and D. Baltimore. 1990. Cloning of the p50 DNA binding subunit of NF-κB: homology to rel and dorsal. Cell 62:1019–1029.
   PubMed Web of Science ®Google Scholar
• Giot, J. F., I. Mikaelian, M. Buisson, E. Manet, I. Joab, J. C. Nicolas, and A. Sergeant. 1991. Transcriptional interference between the EBV transcription factors EB1 and R: both DNA- binding and activation domains of EB1 are required. Nucleic Acids Res. 19:1251–1258.
   PubMedGoogle Scholar
• Goldfeld, A. E., J. L. Strominger, and C. Doyle. 1991. Human tumor necrosis factor a gene regulation in phorbol ester stimulated T and B cell lines. J. Exp. Med. 174:73–81.
   PubMed Web of Science ®Google Scholar
• Gorman, C. M., L. F. Moffat, and B. H. Howard. 1982. Recombinant genomes which express chloramphenicol acetyltransferase in mammalian cells. Mol. Cell. Biol. 2:1044–1051.
   PubMed Web of Science ®Google Scholar
• Hammarskjold, M. L., and M. C. Simurda. 1992. Epstein-Barr virus latent membrane protein transactivates the human immunodeficiency virus type 1 long terminal repeat through induction of NF-κB activity. J. Virol. 66:6496–6501.
   PubMed Web of Science ®Google Scholar
• Hardwick, J. M., P. M. Lieberman, and S. D. Hayward. 1988. A new Epstein-Barr virus transactivator, R, induces expression of a cytoplasmic early antigen. J. Virol. 62:2274–2284.
   PubMedGoogle Scholar
• Haskill, S., A. A. Beg, S. M. Tompkins, J. S. Morris, A. D. Yurochko, J. A. Sampson, K. Mondai, P. Ralph, and A. S. Baldwin. 1991. Characterization of an immediate-early gene induced in adherent monocytes that encodes IκB-like activity. Cell 65:1281–1289.
   PubMed Web of Science ®Google Scholar
• Hirai, H., J. Fujisawa, T. Suzuki, K. Ueda, M. Muramatsu, A. Tsuboi, N. Arai, and M. Yoshida. 1992. Transcriptional activator Tax of HTLV-1 binds to the NF-κB precursor pl05. Oncogene 7:1737–1742.
   PubMed Web of Science ®Google Scholar
• Holley-Guthrie, E. A., E. B. Quinlivan, E. C. Mar, and S. Kenney. 1990. The Epstein-Barr virus (EBV) BMRF1 promoter for early antigen (EA-D) is regulated by the EBV transactivators, BRLF1 and BZLF1, in a cell-specific manner. J. Virol. 64:3753–3759.
   PubMedGoogle Scholar
• Kenney, S. Unpublished data.
   Google Scholar
• Kenney, S., E. Holley-Guthrie, E. C. Mar, and M. Smith. 1989. The Epstein-Barr virus BMLF1 promoter contains an enhancer element that is responsive to the BZLF1 and BRLF1 transactivators. J. Virol. 63:3878–3883.
   PubMed Web of Science ®Google Scholar
• Kenney, S., J. Kamine, E. Holley-Guthrie, E. C. Mar, J. C. Lin, D. Markovitz, and J. Pagano. 1989. The Epstein-Barr virus immediate-early gene product, BMLF1, acts in trans by a posttranscriptional mechanism which is reporter gene dependent. J. Virol. 63:3870–3877.
   PubMedGoogle Scholar
• Kenney, S. C., E. Holley-Guthrie, E. B. Quinlivan, D. Gutsch, Q. Zhang, T. Bender, J. F. Giot, and A. Sergeant. 1992. The cellular oncogene c-myb can interact synergistically with the Epstein-Barr virus BZLF1 transactivator in lymphoid cells. Mol. Cell. Biol. 12:136–146.
   PubMedGoogle Scholar
• Kieff, E., and D. Leibowitz. 1990. Epstein-Barr virus and its replication, p. 1889–1920. In B. N. Fields, D. M. Knipe, R. M. Chanock, M. S. Hirsch, J. L. Melnick, T. P. Monath, and B. Roizman (ed.), Virology. Raven Press, New York.
   Google Scholar
• Kieran, M., V. Blank, F. Logeat, J. Vandekerckhove, F. Lottspeich, B. O. Le, M. B. Urban, P. Kourilsky, P. A. Baeuerle, and A. Israel. 1990. The DNA binding subunit of NF-κB is identical to factor KBF1 and homologous to the rel oncogene product. Cell 62:1007–1018.
   PubMed Web of Science ®Google Scholar
• Kouzarides, T., G. Packham, A. Cook, and P. J. Farrell. 1991. The BZLF1 protein of EBV has a coiled coil dimerisation domain without a heptad leucine repeat but with homology to the C/EBP leucine zipper. Oncogene 6:195–204.
   PubMedGoogle Scholar
• Laherty, C. D., H. M. Hu, A. W. Opipari, F. Wang, and V. M. Dixit. 1992. The Epstein-Barr virus LMP1 gene product induces A20 zinc finger protein expression by activating nuclear factor κB. J. Biol. Chem. 267:24157–24160.
   PubMed Web of Science ®Google Scholar
• Lai, J. S., and W. Herr. 1992. Ethidium bromide provides a simple tool for identifying genuine DNA-independent protein associations. Proc. Natl. Acad. Sci. USA 89:6958–6962.
   PubMed Web of Science ®Google Scholar
• LeClair, K. P., M. A. Blanar, and P. A. Sharp. 1992. The p50 subunit of NF-κB associates with the NF-IL6 transcription factor. Proc. Natl. Acad. Sci. USA 89:8145–8149.
   PubMedGoogle Scholar
• Lenardo, M. J., and D. Baltimore. 1989. NF-κB: a pleiotropic mediator of inducible and tissue-specific gene control. Cell 58:227–229.
   PubMed Web of Science ®Google Scholar
• Li, J. S., B. S. Zhou, G. E. Dutschman, S. P. Grill, R. S. Tan, and Y. C. Cheng. 1987. Association of Epstein-Barr virus early antigen diffuse component and virus-specified DNA polymerase activity. J. Virol. 61:2947–2949.
   PubMed Web of Science ®Google Scholar
• Lieberman, P. M., and A. J. Berk. 1991. The Zta trans-activator protein stabilizes TFIID association with promoter DNA by direct protein-protein interaction. Genes Dev. 5:2441–2454.
   PubMedGoogle Scholar
• Lieberman, P. M., J. M. Hardwick, and S. D. Hayward. 1989. Responsiveness of the Epstein-Barr virus NotI repeat promoter to the Z transactivator is mediated in a cell-type-specific manner by two independent signal regions. J. Virol. 63:3040–3050.
   PubMedGoogle Scholar
• Manet, E., H. Gruffat, M. C. Trescol-Biemont, N. Moreno, P. Chambard, J. F. Giot, and A. Sergeant. 1989. Epstein-Barr virus bicistronic mRNAs generated by facultative splicing code for two transcriptional trans-activators. EMBO J. 8:1819–1826.
   PubMedGoogle Scholar
• Marschall, M., U. Leser, R. Seibl, and H. Wolf. 1989. Identification of proteins encoded by Epstein-Barr virus trans-activator genes. J. Virol. 63:938–942.
   PubMedGoogle Scholar
• Miller, G. 1990. Epstein-Barr virus: biology, pathogenesis, and medical aspects, p. 1921–1958. In B. N. Fields, D. M. Knipe, R. M. Chanock, M. S. Hirsch, J. L. Melnick, T. P. Monath, and B. Roizman (ed.), Virology. Raven Press, New York.
   Google Scholar
• Muesing, M. A., D. H. Smith, and D. J. Capon. 1987. Regulation of mRNA accumulation by a human immunodeficiency virus trans-activator protein. Cell 48:691–701.
   PubMedGoogle Scholar
• Nabel, G., and D. Baltimore. 1987. An inducible transcription factor activates expression of human immunodeficiency virus in T cells. Nature (London) 326:711–713.
   PubMed Web of Science ®Google Scholar
• Narayanan, R., J. F. Klement, S. M. Ruben, K. A. Higgins, and C. A. Rosen. 1992. Identification of a naturally occurring transforming variant of the p65 subunit of NF-κB. Science 256:367–370.
   PubMedGoogle Scholar
• Nelsen, B., L. Hellman, and R. Sen. 1988. The NF-κB-binding site mediates phorbol ester-inducible transcription in nonlymphoid cells. Mol. Cell. Biol. 8:3526–3531.
   PubMedGoogle Scholar
• Neri, A., C. C. Chang, L. Lombardi, M. Salina, P. Corradini, A. T. Maiolo, R. S. Chaganti, and R. Dalla-Favera. 1991. B cell lymphoma-associated chromosomal translocation involves candidate oncogene lyt-10, homologous to NF-κB p50. Cell 67:1075–1087.
   PubMed Web of Science ®Google Scholar
• Nolan, G. P., and D. Baltimore. 1992. The inhibitory ankyrin and activator Rel proteins. Curr. Opin. Genet. Dev. 2:211–220.
   PubMed Web of Science ®Google Scholar
• Nolan, G. P., S. Ghosh, H. C. Liou, P. Tempst, and D. Baltimore. 1991. DNA binding and IκB inhibition of the cloned p65 subunit of NF-κB, a rel-related polypeptide. Cell 64:961–969.
   PubMed Web of Science ®Google Scholar
• Quinlivan, E. B., E. A. Holley-Guthrie, M. Norris, D. Gutsch, S. L. Bachenheimer, and S. C. Kenney. 1993. Direct BRLF1 binding is required for cooperative BZLF1/BRLF1 activation of the Epstein-Barr virus early promoter, BMRF1. Nucleic Acids Res. 21:1999–2007.
   PubMed Web of Science ®Google Scholar
• Riviere, Y., V. Blank, P. Kourilsky, and A. Israel. 1991. Processing of the precursor of NF-κB by the HIV-1 protease during acute infection. Nature (London) 350:625–626.
   PubMed Web of Science ®Google Scholar
• Rong, B. L., T. A. Libermann, K. Kogawa, S. Ghosh, L. X. Cao, L. D. Pavan, and E. C. Dunkel. 1992. HSV-1-inducible proteins bind to NF-κB-like sites in the HSV-1 genome. Virology 189:750–756.
   PubMedGoogle Scholar
• Rooney, C. M., D. T. Rowe, T. Ragot, and P. J. Farrell. 1989. The spliced BZLF1 gene of Epstein-Barr virus (EBV) transactivates an early EBV promoter and induces the virus productive cycle. J. Virol. 63:3109–3116.
   PubMed Web of Science ®Google Scholar
• Ruben, S. M., P. J. Dillon, R. Schreck, T. Henkel, C. H. Chen, M. Maher, P. A. Baeuerle, and C. A. Rosen. 1991. Isolation of a rel-related human cDNA that potentially encodes the 65-kD subunit of NF-κB. Science 251:1490–1493.
   PubMedGoogle Scholar
• Ruben, S. M., R. Narayanan, J. F. Klement, C. H. Chen, and C. A. Rosen. 1992. Functional characterization of the NF-κB p65 transcriptional activator and an alternatively spliced derivative. Mol. Cell. Biol. 12:444–454.
   PubMedGoogle Scholar
• Ryseck, R. P., P. Bull, M. Takamiya, V. Bours, U. Siebenlist, P. Dobrzanski, and R. Bravo. 1992. RelB, a new Rel family transcription activator that can interact with p50-NF-κB. Mol. Cell. Biol. 12:674–684.
   PubMedGoogle Scholar
• Sassone-Corsi, P., A. Wildeman, and P. Chambon. 1985. A trans-acting factor is responsible for the simian virus 40 enhancer activity in vitro. Nature (London) 313:458–463.
   PubMed Web of Science ®Google Scholar
• Schule, R., and R. M. Evans. 1991. Cross-coupling of signal transduction pathways: zinc finger meets leucine zipper. Trends Genet. 7:377–381.
   PubMed Web of Science ®Google Scholar
• Sen, R., and D. Baltimore. 1986. Inducibility of κ immunoglobulin enhancer-binding protein NF-κB by a posttranslational mechanism. Cell 47:921–928.
   PubMed Web of Science ®Google Scholar
• Sen, R., and D. Baltimore. 1986. Multiple nuclear factors interact with the immunoglobulin enhancer sequences. Cell 46:705–716.
   PubMed Web of Science ®Google Scholar
• Shimizu, N., S. Sakuma, Y. Ono, and K. Takada. 1989. Identification of an enhancer-type sequence that is responsive to Z and R trans-activators of Epstein-Barr virus. Virology 172:655–658.
   PubMedGoogle Scholar
• Sista, N. D., J. S. Pagano, W. Liao, and S. Kenney. 1993. Retinoic acid is a negative regulator of the Epstein-Barr virus protein (BZLF1) that mediates disruption of latent infection. Proc. Natl. Acad. Sci. USA 90:3894–3898.
   PubMedGoogle Scholar
• Sixbey, J. W., J. C. Nedrud, N. Raab-Traub, R. A. Hanes, and J. S. Pagano. 1984. Epstein-Barr virus replication in oropharyngeal epithelial cells. N. Engl. J. Med. 310:1225–1230.
   PubMed Web of Science ®Google Scholar
• Stein, B., P. C. Cogswell, and A. S. Baldwin. 1993. Functional and physical associations between NF-κB and C/EBP family members: a Rel domain-bZIP interaction. Mol. Cell. Biol. 13:3964–3974.
   PubMed Web of Science ®Google Scholar
• Stein, B., H. J. Rahmsdorf, A. Steffen, M. Litfin, and P. Herrlich. 1989. UV-induced DNA damage is an intermediate step in UV-induced expression of human immunodeficiency virus type 1, collagenase, c-fos, and metallothionein. Mol. Cell. Biol. 9:5169–5181.
   PubMed Web of Science ®Google Scholar
• Steward, R. 1987. Dorsal, an embryonic polarity gene in Drosophila is homologous to the vertebrate proto-oncogene, c-rel. Science 238:692–694.
   PubMed Web of Science ®Google Scholar
• Takada, K., N. Shimizu, S. Sakuma, and Y. Ono. 1986. trans activation of the latent Epstein-Barr virus (EBV) genome after transfection of the EBV DNA fragment. J. Virol. 57:1016–1022.
   PubMed Web of Science ®Google Scholar
• Urier, G., M. Buisson, P. Chambard, and A. Sergeant. 1989. The Epstein-Barr virus early protein EB1 activates transcription from different responsive elements including AP-1 binding sites. EMBO J. 8:1447–1453.
   PubMedGoogle Scholar
• Walker, W. H., B. Stein, P. A. Ganchi, J. A. Hoffman, P. A. Kaufman, D. W. Ballard, M. Hannink, and W. C. Greene. 1992. The v-rel oncogene: insights into the mechanism of transcriptional activation, repression, and transformation. J. Virol. 66:5018–5029.
   PubMedGoogle Scholar
• Wilhelmsen, K. C., K. Eggleton, and H. M. Temin. 1984. Nucleic acid sequences of the oncogene v-rel in reticuloendotheliosis virus strain T and its cellular homolog, the proto-oncogene c-rel. J. Virol. 52:172–182.
   PubMed Web of Science ®Google Scholar
• Young, L. S., R. Lau, M. Rowe, G. Niedobitek, G. Packham, F. Shanahan, D. T. Rowe, D. Greenspan, J. S. Greenspan, A. B. Rickinson, and P. J. Farrell. 1991. Differentiation-associated expression of the Epstein-Barr virus BZLF1 transactivator protein in oral hairy leukoplakia. J. Virol. 65:2868–2874.
   PubMed Web of Science ®Google Scholar
• Zalani, S., E. A. Holley-Guthrie, D. E. Gutsch, and S. C. Kenney. 1992. The Epstein-Barr virus immediate-early promoter BRLF1 can be activated by the cellular Spl transcription factor. J. Virol. 66:7282–7289.
   PubMedGoogle Scholar
• Zhang, Q., D. Gutsch, and S. Kenney. 1994. Functional and physical interaction between p53 and BZLF1: implications for Epstein-Barr virus latency. Mol. Cell. Biol. 14:1929–1938.
   PubMed Web of Science ®Google Scholar
• zur Hausen, H., F. J. O'Neill, and K. F. Ulrich. 1978. Persisting oncogenic herpesvirus induced by the tumour promoter TPA. Nature (London) 272:373–375.
   PubMed Web of Science ®Google Scholar